Sökning: id:"swepub:oai:DiVA.org:uu-260594" >
Comparison of dabig...
-
Brambatti, Michela
(författare)
Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation : Results from the RE-LY trial
- Artikel/kapitelEngelska2015
Förlag, utgivningsår, omfång ...
-
Elsevier BV,2015
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-260594
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-260594URI
-
https://doi.org/10.1016/j.ijcard.2015.05.141DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Objective: Diabetes mellitus (DM) is frequent among patients with atrial fibrillation (AF). The RE-LY trial permits evaluation of patient characteristics, outcomes and the effectiveness of dabigatran etexilate among diabetic individuals. Methods: Patient characteristics and outcomes were compared between diabetic and non-diabetic patients and the relative efficacy of each dose of dabigatran (150 mg bid and 110 mg bid) versus warfarin was evaluated. Results: Of 18,113 patients in RE-LY, 4221 patients (23.3%) had DM. Patients with DM were younger (70.9 vs. 71.7 years), more likely to have hypertension (86.6% vs. 76.5%), coronary artery disease (37.4% vs. 24.9%) and peripheral vascular disease (5.6% vs. 3.2%); (all p < 0.01). Time in therapeutic range for warfarin-treated patients was 65% for diabetic versus 68% for non-diabetic patients (p < 0.001). Regardless of assigned treatment, stroke or systemic embolism was more common among patients with DM (1.9% per year vs. 1.3% per year, p < 0.001). DM was also associated with an increased risk of death (5.1% per year vs. 3.5% per year, p < 0.001) and major bleeding (4.2% per year vs. 3.0% per year, p < 0.001). The absolute reduction in stroke or systemic embolism with dabigatran compared to warfarin was greater among patients with DM than those without DM (dabigatran 110 mg: 0.59% per year vs. 0.05% per year; dabigatran 150 mg: 0.89% per year vs. 0.51% per year). Conclusions: Compared to non-DM patients, AF patients with DM derive a greater absolute risk reduction in embolic events when treated with dabigatran. ClinicalTrials.gov Identifier: NCT00262600.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Darius, Harald
(författare)
-
Oldgren, JonasUppsala universitet,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)jonaoldg
(författare)
-
Clemens, Andreas
(författare)
-
Noack, Herbert H.
(författare)
-
Brueckmann, Martina
(författare)
-
Yusuf, Salim
(författare)
-
Wallentin, LarsUppsala universitet,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)larswall
(författare)
-
Ezekowitz, Michael D.
(författare)
-
Connolly, Stuart J.
(författare)
-
Healey, Jeff S.
(författare)
-
Uppsala universitetUppsala kliniska forskningscentrum (UCR)
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:International Journal of Cardiology: Elsevier BV196, s. 127-1310167-52731874-1754
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Brambatti, Miche ...
-
Darius, Harald
-
Oldgren, Jonas
-
Clemens, Andreas
-
Noack, Herbert H ...
-
Brueckmann, Mart ...
-
visa fler...
-
Yusuf, Salim
-
Wallentin, Lars
-
Ezekowitz, Micha ...
-
Connolly, Stuart ...
-
Healey, Jeff S.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
International Jo ...
- Av lärosätet
-
Uppsala universitet